Stifel Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $318

Benzinga Newsdesk www.benzinga.com Negative 54.5%

Neg 54.5% Neu 0% Pos 0%

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $444 to $318.